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DSC  desmocollin 
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ECG  electrocardiogram 
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H&E  haematoxylin & eosin  
HIV  human immunodeficiency virus 
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NHLS  National Health Laboratory Service 
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PSAX  parasternal short-axis 
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RESEARCH PROPOSAL  
 
   Title  
An immunohistochemical classification of endomyocardial biopsy specimens from the 
South African Arrhythmogenic Right Ventricular Cardiomyopathy Registry 
 
Investigator 
Dr Nicole Morse 
MRSNIC013    
Registrar 
Division of Anatomical Pathology 
 
Introduction 
Arrhythmogenic right ventricular cardiomyopathy / dysplasia (ARVC/D) is a genetic 
disease causing fibro-fatty replacement of the right ventricular myocardium, resulting in 
cardiac arrhythmias and sudden death. Part of the diagnostic work up for these patients 
includes a biopsy of the endocardium which has historically been difficult to interpret and 
of limited value in the early stages of disease. This study will focus on novel 
immunohistochemical stains of the cardiac desmosomes. These will be used to try to aid 
in the early diagnosis of ARVC. 
 
Supervisors 
Professor H Wainwright, Principle specialist, Division of anatomical pathology University 
of Cape Town and Groote Schuur Hospital.  
Professor B Mayosi, Head Department of Medicine, University of Cape Town and Groote 
Schuur Hospital. Principle investigator: Arrhythmogenic Right Ventricular 
Cardiomyopathy (ARVC) registry of South Africa. 
 
 
Aims and objectives 
 
Aim:  




1: To ascertain if immunohistochemistry of cardiac desmosomes on biopsies from a 
septal location are of diagnostic value. 
2: If immunohistochemistry is successful on cardiac biopsies to determine if there is a role 
for immunohistochemistry on skin biopsies. 
 
Background 
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic disease 
of autosomal dominant and occasionally recessive inheritance with variability in its 
penetrance and expression[1] .  It has been defined by the World Health Organisation/ 
International Society and Federation of Cardiology Task Force as a myocardial disease 
“characterised by fibro-fatty replacement the right ventricle (RV) myocardium, initially with 
typical regional and later global RV and some left ventricular involvement”. It is 
associated with ventricular dilatation, arrhythmias, ECG abnormalities and sudden 
cardiac death. 
 
Mutations have been described in five genes coding for the cardiac desmosome: 
Plakoglobin, desmoplakin, plakophilin 2 and desmoglein 2. Plakoglobin and desmoplakin 
mutations code for the autosomal recessive Naxos disease[1]. 
It has recently been reported that regardless of the genetic mutation, plakoglobin is the 




Endomyocardial biopsy (EMB) showing fibrofatty replacement of the RV is recognised as 
a major criteria in the diagnosis of ARVD[3]. EMB is of value in excluding other causes of 
cardiomyopathy and arrhythmias such as amyloidosis, haemochromatosis and 
myocarditis[4]. 
 
Histomorphological parameters for ARVC have been defined as follows: residual 
myocytes less than 45%, fibrous tissue more than 40%, fatty tissue more than 3%.  
However it is recognized that that there will be a difference in these percentages 
depending on the site of the right ventricle biopsied as well as the distribution of the 
disease  [4]. 
As ARVD is a segmental disease often only one of the biopsy samples will be diagnostic 
[5]. 
 
The right ventricular septum would be a preferred site of biopsy to avoid the complication 
of perforation, following biopsy from the thin RV free wall[4]. The septum has traditionally 
not been a recommended site for biopsy due to a low incidence of fibrosis and fatty 
infiltration [4]. However results of immunofluorescence stains have shown significant 
changes at this site in the absence of morphologic abnormalities [2].  
 
Naxos disease is an autosomal recessive condition characterised by a triad of ARVD, 
wooly hair and plantopalmar keratoderma. It caused by a deletion of the plakoglobin gene 
on chromosome 17q21.  
Plakoglobin is found in desmosomes within the epidermis [6].  It has been speculated that 
reduced expression of plakoglobin could be demonstrated by immunohistochemistry in 
skin biopsies from patients with ARVD. This could be of diagnostic significance if 
immunohistochemical stains prove the reduced expression as would obviate the need for 




The South African Arrhythmogenic Right Ventricular Cardiomyopathy Registry has been 
established under the Working Group of Registries of the Cardiac Arrhythmia Society of 
Southern Africa.  The registry is based at the Cardiac Clinic, Groote Schuur Hospital, 
Cape Town.  
Suspected cases from across the country are referred to the registry and if they meet the 
diagnostic criteria suspected patients are asked to partake in the registry. The registry 
has 6 branches: DNA and tissue bank; Epidemiology and family screening; Risk 
assessment and evaluation of therapy; Imaging; Pathology registry and tissue bank (EMB 
samples, explanted hearts) and Diagnostic validation [7].  
 












We aim to collect ten cases of ARVC (diagnosed using clinical and radiologic 
characteristics as set out by the ARVC task force criteria), ten cases of HIV associated 
cardiomyopathy, ten cases of dilated cardiomyopathy (DCMO) and ten cases of 
transplanted donor hearts to use as normal controls. These will be retrieved from the 
retrieved from archives of the Division of Anatomical pathology at University of Cape 
Town.  
 
Endomyocardial biopsy (EMB) sampling: 
 
Biopsies already taken and registered with the South African Arrhythmogenic Right 
Ventricular Cardiomyopathy Registry will be retrieved from archives of the Division of 
Anatomical pathology at University of Cape Town. 
For future biopsies the clinician will submit up to 4 biopsies in 10% formalin, each in 
separate container labeled with the anatomic site in the right ventricle. 
 
Endomyocardial biopsy Processing: 
 
Formalin fixed specimens will be placed in numbered cassettes and labeled    
“EMB”. 
Cassettes will be placed in tissue processor (Tissue Tec VIP 4) to be dehydrated by 
graded alcohols, washed and impregnated with paraffin. 
The tissue is then orientated in wax blocks. 
 
 
The blocks are cut on a microtome into 3-5um slices. 
Routine stains include Haematoxylin & Eosin (H&E), Elastin Von Gieson (EVG) / Picro-
sirius red (PSR), Congo red, Perl’s Prussian blue. 
Slides to be issued to Dr HC Wainwright or Dr NJ Morse 
For already processed tissues the H&E slides will be reviewed and PSR, Congo red and 




Immunohistochemistry is used to detect antigens that will aid, confirm or exclude the 
diagnosis of a particular pathology or disease. 
 
A primary antibody will bind to the targeted antigen. 
A secondary antibody will bind to the primary antigen-antibody complex 
In the presence of peroxidase and chromogen the secondary antibody turns brown at the 
site of the antigen. 
 
The procedure used for immunohistochemistry is as follows: 
1. Sections will be cut at 2-4 microns 
2. Sections are floated onto APES coated slides and blotted 
3. Heat fix the sections onto the slides by leaving slides on hot plate (60°C) 
4. Dewax slides in xylol, rehydrate in graded alcohols.  
5. Wash slides in running tap water 
6. Perform appropriate antigen retrieval (citrate or EDTA depending on antibody 
used, see immunohistochemistry optimization section). 
7. Block endogenous peroxidase activity by treating the slides with 1% hydrogen 
peroxide in methanol or distilled water for 5-10 minutes. Use a coplin jar. 
8. Rinse in running tap water 
 
 
9. Block for non-specific background staining by treating slides with normal goat 
serum (1:20) for 5-10 minutes 
10. Drain the normal serum from the slides 
11. Apply appropriately diluted primary antibody for 45 minutes.  (See 
immunohistochemistry optimizing section on dilution values for each antibody.) 
12. Rinse thoroughly with phosphate buffered saline (pH 7.6) 
13.  Apply Envision reagent, goat anti-rabbit antibody (secondary antibody),  for 25-30 
minutes 
14.  Repeat step 12 
15.  Apply chromogenic substrate (1ml buffer and 1 drop diaminobenzidene)    for 3-5 
minutes 
16.  Repeat step 12 
17.  Immerse slides in 1% copper sulphate for 3-5 minutes to enhance the 
diaminobenzidene 
18.  Rinse in running tap water 
19.  Counterstain in haematoxylin 
20.  Repeat step 12 
21.  Rinse the slides in Scotts tap water 
22.  Repeat step 12 
23.  Dehydrate and mount in entellan 
 
Sections of the biopsy will be cut for immunohistochemical staining. 
Stains used will be plakoglobin, Connexin 43, N-cadherin. 
 
Plakoglobin (gamma-catenin): 
Is a protein linking adhesion molecule present at the intercalated disc. 
Reduced expression of plakoglobin has been shown in patients with ARVD [2]. 
 
 
This reduced signal is not only found in the RV free wall but also the septum and left 
ventricle. Reduced expression of plakoglobin appears to be the final common 
pathway in pathogenesis of ARVD, independent of which primary protein is affected 
[1] 
The antibody can be purchased from Southern Cross Biotechnology. 
 
Connexin 43: 
Is a gap junction protein allowing direct gap junction intracellular communication and 
associated with growth regulation [8]. 
Shows reduced expression in all end stage heart failure specimens [2] 
Antibody can be purchased from Laboratory Specialist Services. 
 
N -cadherin: 
N-cadherin is a non-desmosomal adhesion molecule and will be used as an internal 
marker of tissue quality.  Decreased expression is seen as an indication of poor 
quality tissue on which a diagnosis cannot be made.  [2] 
N-cadherin can be purchased from Biocom Biotec. 
 
Optimising the antibodies: 
 
Due to the limited tissue available in EMB samples initial attempts at optimizing the 
antibodies were done on tissue from explanted hearts or postmortem tissues. 
In the first run myocardium from a term, fresh still birth was used as normal control tissue.  
 
ARVD =Arrhythmogenic right ventricular dysplasia 














1:100 EDTA 45 min Room temp Very strong staining 
Background over stained 
IHD 
8872/08 
1:100 EDTA 45 min Room temp Very strong staining 




1:100 EDTA 45 min Room temp Very strong staining 
Background over stained 
 










1:200 EDTA 45 min Room temp Strong staining (aberrant) 
IHD 
8872/08 




















1:100 EDTA 45 min Room temp Moderate staining (aberrant) 
IHD 
8872/08 




1:100 EDTA 45 min Room temp No staining (aberrant) 
 
Due to the poor staining of Connexin 43 and G-catenin in the control tissue it was felt that 
adult heart should be used in the next run as a control. 
The N-cadherin was diluted to1:200 in the second run to try remove the background 
staining. 
New cases were selected for the ARVD and IHD as the both the Connexin 43 and G-
catenin were showing aberrant staining.
 
 















1:100 EDTA 45 min Room temp Weak staining 
Control  
(adult) 
1:100 EDTA 45 min Room temp Good staining 
 










1:200 EDTA 45 min Room temp No Staining 
IHD 
23349/07 
1:200 EDTA 45 min Room temp No staining 
Control  
(adult) 





2nd run: G-catenin 
Tissue Antibody 
dilution 







1:200 EDTA 45 min Room temp Good staining 
IHD 
23349/07 
1:200 EDTA 45 min Room temp  Weak staining 
Control  
(adult) 
1:200 EDTA 45 min Room temp Good staining 
 
Persistent staining of G -catenin in ARVD tissue was not expected, however the 
supplementary appendix to the  Asimaki et al article “A New Diagnostic Test for 
Arrhythmogenic Right Ventricular Cardiomyopathy” specifies the use of citrate buffer [2]. 
This will be used in the 3rd run.  
The poor staining of Connexin 43 cannot be explained as only the tissue samples were 
changed between run 1 and 2. 
 
For the 3rd run new tissue samples were chosen, this time from endomyocardial biopsies. 
The control tissue used in this run was an endomyocardial biopsy from a donor heart 
transplant taken 1 week after surgery. This tissue had no evidence of rejection or 
structural pathology. 
 
Once the antibodies have been optimized that procedure will become the standardized 






Skin biopsy samples: 
Samples already submitted will be retrieved from the archives of the division of Anatomical 
Pathology, University of Cape Town. 
For future biopsies the following protocol is recommended: 
4mm punch biopsy of skin from the palm submitted in 10% formalin. 
4mm punch biopsy from the forearm submitted in 2.5 % glutaraldehyde for electron 
microscopy. 
 
Skin biopsy processing: 
Paraffin sections will be prepared as for the EMB specimens. 
Routine staining will only be an H&E. 
Specimen will be examined for morphologic abnormalities of the keratin and epidermis. 
Skin biopsy immunohistochemistry: 
If the N-cadherin and plakoglobin immunohistochemistry is statistically significant on the 
cardiac biopsies then the same antibodies will be applied to the skin biopsies. 
After antibody optimisation 10 skin biopsies from genetically or clinically proven ARVD 
patients and 10 skin biopsies from normal patients will be retrieved from archives. 
The immunohistochemical panel of N-cadherin and G-catenin will be applied to the samples. 
With the pathologists blinded to the case the slides will be reviewed by Dr HC Wainwright 







Endomyocardial biopsy immunohistochemistry: 
Decreased plakoglobin expression is expected in ARVD patients’ versus normal controls 
with normal N-cadherin staining in both groups. 
      
    Skin immunohistochemistry: 
Decreased plakoglobin expression is expected in ARVD patients’ versus normal controls   




If the results of the immunohistochemistry are statistically significant then the antibodies 
will be used as a diagnostic investigation in our routine practice for future EMB 
specimens.  
 
If the antibodies are shown to be of use in EMB specimens then further research can 
done to see if staining of skin biopsies could be used in the diagnosis of ARVD rather 
than the invasive procedure of an EMB. This would be a great cost saving strategy as 
well as reducing the morbidity associated with endomyocardial biopsies. 
 
This project falls under the collaborative Arrhythmogenic Right Ventricular 
Cardiomyopathy (ARVC) registry of South Africa, a multicentre study established under 
the Working Group of Registries of the Cardiac Arrhythmia Society of Southern Africa. 
 





Budget requested from the NHLS Research Trust 
  
 Consumables Cost - Rands 
1 Connexin 43 antibody 100ul 3941 
2 Connexin 43 antibody 100ul 3941 
3 N - cadherin antibody 100ul 8946 
4 N - cadherin antibody 100ul 8946 
5 G - catenin antibody 1ml 4592 
6 G - catenin antibody 1ml 4592 
7 Goat anti-rabbit antibody  10876 
8 Diaminobenzidene 110ml 1845 
9 Goat serum 10ml 300 
10 Phosphate buffered saline 1388 
11 Entellan 500ml 264 
12 Glass slides x 50 90 
13 Glass slides x 50 90 
14 Glass slides x 50 90 
15 Glass slides x 50 90 
16 Coverslips x 100 46 
17 Coverslips x 100 46 
18 Microtome blades x 50 818 
19 Histological sections 12000 
20 Disposable tubes x 1000 719 
22 Pipette tips  (100ul) x 900 300 
23 Pipette tips  (200ul) x 900 300 
 
 
24 Pipette tips  (1000ul) x 900 300 
25 Paper towels x 24 rolls 91 
26 Conference attendance 2500 
27 Conferance travel 4000 
28 Antibody freight charges (Connexin 43) 3000 
29 Antibody freight charges (G-catenin) 3000 
30 Antibody freight charges (N-cadherin) 3000 
 
Total       R 80 111.00 
 
Budget justification 
The budget submitted includes the costs of the primary antibodies, secondary antibodies 
and consumables (pipette tips, buffers, slides) all used in the immunohistochemistry 
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 Protocol Summary 
 
Title  
An immunohistochemical classification of endomyocardial biopsy specimens from the South 
African Arrhythmogenic Right Ventricular Cardiomyopathy Registry 
 
Investigator 
Dr Nicole Morse (Division of Anatomical pathology, UCT) 
 
Introduction 
Arrhythmogenic right ventricular cardiomyopathy / dysplasia (ARVC/D) is a genetic disease 
causing fibro-fatty replacement of the right ventricular myocardium, resulting in cardiac 
arrhythmias and sudden death. Part of the diagnostic work up for these patients includes a biopsy 
of the endocardium which has historically been difficult to interpret and of limited value in the early 
stages of disease. This study will focus on novel immunohistochemical stains of the cardiac 
desmosomes.  These will be used to try to aid in the early diagnosis of ARVC. 
 
 Aim of the study  
To classify the biopsy specimens of the ARVC registry into diagnostic, suspicious and non-
diagnostic categories. This will be done using immunohistochemical techniques. 
 
Materials 
Tissue blocks from ARVC registry patients (endomyocardial biopsies), patients known with 
dilated cardiomyopathy (DCMO), human immunodeficiency virus (HIV) associated 
cardiomyopathy and heart transplant biopsies will be retrieved from the Division of 






Immunohistochemistry will be applied to and compared between 10 cases each of ARVC, 
DCMO, HIV associated cardiomyopathy and cardiac transplant biopsies.  
 
Impact 
If the results of the immunohistochemistry are statistically significant then the antibodies will 
be used as a diagnostic investigation in our routine practice for future EMB specimens. 
If skin biopsies show a statistically significant decrease in plakoglobin staining, skin biopsies 
could be used in the diagnosis of ARVD rather than the invasive procedure of an EMB.  
 
Results 
It will be used for a MMed (Anat Path) degree for Dr N Morse 
To be submitted in peer-reviewed journals 
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This literature review aims to assess the role of pathology, particularly routine histopathology 
and immunohistochemistry in the diagnosis of ARVC. 
This will form part of a MMed minor dissertation in anatomical pathology. 
SEARCH STRATEGY 
A PubMed search using the words “arrhythmogenic right ventricular cardiomyopathy / 
dysplasia” was performed up until January 2014. Articles with genetic, histopathology and 
immunohistochemical content were focused on. Clinical and radiologic articles were 
excluded. 
QUALITY CRITERIA 









ARVC is defined as a disease of the heart muscle characterised, clinically, by non-ischaemic 
ventricular arrhythmias originating from the right heart muscle [1]. Pathologically it is defined 
by fibro-fatty replacement of the right ventricular myocytes [2].  Originally felt to be a 
developmental defect of the RV myocardium, similar to Uhl’s anomaly, the disease was 
given the name “Arrhythmogenic right ventricular “dysplasia”.  Ongoing developments into 
the genetic and pathophysiology of the disease the concept evolved into it being accepted 
as a cardiomyopathy by the World health Organisation in 1997.[3] [4, 5]. However, further 
evidence suggesting significant involvement of both left and right ventricles has resulted in 
the term arrhythmogenic cardiomyopathy being used synonymously for ARVC [6]. 
The first historical reference to ARVC was in the eighteenth century when Giovanni Maria 
Lancisi, the physician of the pope, reported 4 generations of a family with right ventricular 
(RV) heart failure and sudden cardiac death (SCD) [7].  It was only in the early eighties that 
ARVC became recognised as a specific disease entity when a case series of 24 patients 
was published in Circulation [8] . 
A genetic basis of transmission of the disease was then reported in 1988 [9]. They described 
an autosomal dominant transmission with a variable penetrance of approximately 50% of 
cases. An autosomal recessive form of the disease had already been described in 1986 [10]. 
This detailed a syndrome of palmoplantar keratoderma and cardiac failure within families 











Clinically patients present between the second and forth decades with palpitations, syncope, 
cardiac arrest and SCD.  Males are more commonly affected than females (male: female 
ratio 3:1) [12, 13].  The reported incidences of symptoms vary between studies. Sudden 
cardiac death has been reported to be as high as 23%, palpitations vary from 27 – 67% and 
syncope from 26 -32% [14, 15] 
Three patterns of the disease have been described:   [16, 17]                                                                                
1 - “Silent” phase with RV cardiomyopathic abnormalities in asymptomatic victims of SCD.                      
2 - “Overt” disease with RV (and possible left ventricular (LV)) structural changes resulting in   
symptomatic arrhythmias.                                                                                                                                    
3 - “End-stage” biventricular cardiomyopathy resulting in progressive cardiac failure  
ARVC is often mis-diagnosed (or not diagnosed) both clinically and at autopsy. Therefore an 
accurate estimate of prevalence is not easy to determine. A large series published on 
sudden deaths from the Veneto region of Italy showed a prevalence of 1:2000  but  general 








Up to 50 % of ARVC cases are autosomal dominant (AD) in transmission with variable 
expression and penetrance [19]. This incomplete penetrance and expression has resulted in 
a search for environmental factors (especially viruses) and other genetic modifiers 
(extradesmosomal genes) in addition to the known mutations.  
Mutations have been identified in the five major components of the desmosome. These 
genes are: PKP2 – plakophilin 2; DSG2 – desmoglein 2; DSP – desmoplakin, DSC2 – 
desmocollin 2 and JUP – plakoglobin (PG)  [20]. The majority of mutations are in the PKP2 
gene. However, regardless of which desmosomal gene has the mutation there is always a 
decrease in plakoglobin protein at the intercalated disc. This decreased expression of 
plakoglobin has therefore become an area of interest as a possible diagnostic marker for 
ARVC [20, 21]. New mutations are being discovered for example transmembrane protein -43 
(TMEM43) is found in families from Newfoundland. This mutation is highly lethal and fully 
penetrant with affected males more likely to develop heart failure early transforming growth 
factor  β-3 (TGFβ3) modulates expression of genes encoding for cell–cell junction stability 
and over-expression may induce myocardial fibrosis by stimulating mesenchymal cells to 
proliferate and produce extracellular matrix components [79]. 
Autosomal recessive transmission is also associated with mutations in the plakoglobin and 
desmoplakin genes [22]. As would be expected in an AR condition the penetrance of the 
disease is almost 100%. The recessive cases always present with the classic hair and skin 
changes (woolly hair and palmoplantar keratoderma). The cardiac presentation is 








BIOPSY AND AUTOPSY FINDINGS 
Fibro-fatty replacement of cardiac myocytes is the histologic hallmark of the disease. This 
predominantly, or at least initially, occurs in the RV [3, 9]. This process is transmural, starting 
in the epicardium and progressing towards the endocardium with sparing of the trabecular 
musculature [5, 8, 16, 23].  
Grossly the heart is of normal weight for age and sex and can be completely unremarkable 
in the early phases of the disease. As the disease progressed the characteristic macroscopic 
findings can be appreciated. On external view the heart appears whitish/yellow over the RV 
were the fat has infiltrated. The RV is dilated and ventricular aneurysms are characteristic 
and may be multiple. The aneurysms are usually found in the “triangle of dysplasia”: the 
inferior, apical and infundibular areas [8]. Involvement of the LV is seen in about half of all 
cases and septal involvement in 20% of cases but this process is usually microscopic [3, 16, 
23]. Only in end stage disease will biventricular involvement be seen grossly, usually in 
autopsy or explanted hearts [3, 24]. Mural thrombi can be found in aneurysms and 
organisation of thrombi results in thickening of the endocardium. 
Two histologic variants have been described: A fatty / lipomatous variant and a fibro-fatty 
variant [3, 25]. The fatty variant is, however, always accompanied by a small amount of 
fibrous tissue and careful sampling is required to identify the fibrosis. This is important as fat 
alone is not diagnostic of ARVC, normal hearts have intramyocardial fat in the antero-lateral 
and apical areas of the RV. In these normal hearts the boundary between the inner 
myocardium and outer subepicardial fat is usually fairly distinct [26]. Adipositas cordis and 
cardiac lipomas are conditions associated with increased adipose tissue. Adipositas cordis 





fat is usually subepicardial and pushes the myocytes apart rather than replacing them [26, 
27]. 
An injury – repair mechanism is proposed as the mechanism responsible for the histologic 
findings [3, 28]. Myocyte death is accompanied by myophagocytolysis and fibrous tissue 
replaces the injured muscle. This is backed up by the findings of an associated chronic 
inflammatory infiltrate in 66 - 75% of cases [22, 23, 29]. Apoptosis is also suggested to play 
a role in the death of myocytes. Increased apoptotic bodies are found in patients with a new 
onset of symptoms [30, 31]. Apoptosis, necrosis and inflammatory infiltrates are common 
findings at autopsy as they are associated with a “hot phase” of the disease from which a 
patient is more likely to die. It is less common to find apoptotic bodies and necrosis in 
endomyocardial biopsy specimens and therefore these features are not needed to make a 
diagnosis of ARVC [30, 32]. 
Genetic investigations into the Wnt/B-cat signalling pathway have revealed how cardiac 
progenitor cells can by stimulated into  adipocytic differentiation [33]. 
Due to the presence of accompanying inflammation it has been suggested that a viral cause 
is responsible for ARVC, especially in patients with no family history. Viral DNA has been 
detected within the myocardium [34] but there is criticism that these are secondary and settle 
in the degenerating myocardium rather than causing it [35]. 
The general consensus is that fat alone is not diagnostic of ARVC. Fat accompanied by 
replacement type fibrosis with or without degenerate myocytes is needed to make a 
histologic diagnosis.[22, 25, 26] 
Various investigators have looked into which histologic findings are most sensitive and 
specific for the diagnosis of ARVC on an endomyocardial biopsy. To this end quantitative 
parameters have been researched to try and determine numerical valves of fibrosis and fat 
required to make the diagnosis of ARVC. In summary here are the various researchers’ 





Angelini et al in 1993 and 1996 [36, 37] reported a 67% sensitivity and 92% specificity if any 
one of the following parameters was present: Residual myocytes <45%, fibrosis >40%, fat 
>3% of the cross sectional area of the biopsy. 
Wichter et al in 1994 [38] used the criteria of either fatty or fibro-fatty infiltration accounting 
for > 25% of the biopsy surface as diagnostic of ARVC. This figure gave them a sensitivity of 
66% 
Turrini et al in 1999 [39] compared the biopsy results to clinical findings and reported fibrosis 
of >30% was a significant predictor of a decreased RV ejection fraction and characteristic 
ECG abnormalities. He did not demonstrate any association between fatty tissue and these 
clinical parameters. This association of fibrosis causing late potential’s on ECG has also 
been demonstrated by both Mehta et al [40] and La Vecchia et al [41] 
Chimenti et al in 2004 [29] showed mean values of myocytes 44%, fat 24% and fibrosis 26% 
can diagnosis ARVC cases from myocarditis and controls. 
Basso et al in 2008 [32] simplified the morphometric values and found that the percentage of 
residual myocytes is the main diagnostic parameter. A value of < 64% is diagnostic of ARVC 
with a sensitivity of 60% and a specificity of 90%. 
It is important to stress that these morphometric parameters are only of diagnostic value if 
taken from the right ventricular free wall, “triangle of dysplasia” and not from the right septum 
or left ventricle [22, 29, 32, 38]. Clinicians are often against biopsying the free wall as it is 
thin and liable to perforate with a resultant haemopericardium. However the  risk of death 
from this procedure is estimated to be <0.2% [42].  ECG guidance of the biopsy has been 
shown to be a safe option with a major complication rate of <0.4% and no deaths reported in 
a series of 4301 procedures [43]. 
As far as histomorphometry can be used in aiding the diagnosis of ARVC one must always 





hypertrophy, cytoplasmic vacuolation and nuclear abnormalities are important histologic 







TASK FORCE CRITERIA 
The accepted gold standard for the diagnosis of ARVC is histological evidence of transmural 
fibro-fatty replacement of the RV myocardium. This is obviously only possible in the autopsy 
setting or on an explanted heart. Endomyocardial biopsy is not transmural and often taken 
from the region of the, uninvolved, septum [22]. This is not of much value in the clinical 
setting and in 1993 a task force was established to set out parameters on which to make a 
diagnosis of ARVC. 
The task force established six areas were the evidence indicated a diagnosis of ARVC could 
be made. These included (I) Global/regional dysfunction and structural alterations; (II) Tissue 
characterisation of walls; (III) Repolarisation abnormalities; (IV) Depolarisation/conduction 
abnormalities; (V) Arrhythmias; (VI) Family history. 
Major and minor criteria were established within the areas according to their specificity for 
the condition. The Task force proposed that the diagnosis of ARVC could be made by the 
presence of two major criteria or one major plus two minor criteria or four minor criteria.  
These criteria required only fibrofatty replacement of the myocardium as a major criterion of 
the diagnosis. They did not require any quantitative values of fibrosis or fat. No minor criteria 
were included in “tissue categorisation of walls”. See table 1. 
At the time it was acknowledged by the task force that this was a working framework and 
that  as more genetic evidence was uncovered more definite criteria could be set out [19]. 
The 1994 criteria were modified to include first degree relatives with incomplete expression 
of the disease. This was done in order to try increase the sensitivity of diagnosis [44]. In 





The big change of the tissue characterisation group between 1994 and 2010 is that a 
quantitative not a qualitative value of fibrofatty replacement is now used. They have used the 
morphometric values proposed by Basso et al as diagnostic criteria [32].  The 2010 criteria 
state that residual myocytes <60% by morphometry (or <50% if estimated), with fibrous 








CELL ADHESION  
Cardiac myocytes have a unique structure which allows electrical impulses to pass from the 
end of one myocyte into the adjacent myocyte, this is called the intercalated disc. Within the 
intercalated disc are gap junctions, which allow electrical coupling of the myocytes by 
allowing free passage of ions across membranes of adjoining myocytes [46]. These gap 
junctions are vital for the coordinated muscle contraction of the heart [33]. Mechanical 
coupling is formed by two structures within the intercalated disc the desmosome and the 
adherens junction. Desmosomes are rigid structures and form a stable adhesion between 
myocytes [47, 48] (See figure 1). Adherens junctions are both mechanical adhesions and 
interact with PI3K to mediate downstream Akt signalling [48]. 
Gap junction remodelling occurs in most forms of heart disease, including dilated 
cardiomyopathies, ischaemic heart disease, hypertrophic conditions and ARVC [49]. 
Remodelling refers to fewer and smaller gap junctions within the intercalated disc; this is 
demonstrated on both electron microscopy and immunohistochemistry [50]. It is felt that the 
characteristic ECG abnormalities and arrhythmias of ARVC are due to gap junction 
remodelling resulting in conduction defects within the myocardium [51]. The major protein 
found in gap junctions is connexin 43 (Cx43)[52] 
The electrical integrity of gap junctions is dependent on surrounding mechanical support. As 
gap junctions are stiff protein structures, they are prone to rupture under shear forces. The 
adjacent adhesion junctions are thought to protect the gap junctions by providing mechanical 
support [53, 54]. 
Adhesion junctions are formed by cadherins (E-cadherin and N-cadherin) on opposite cell 
membranes hooking together to form a zipper-like structure. The cadherins tail in the 





turn link to the actin cytoskeleton via a-catenin [47] .  Initially PG and BC were thought to be 
the same protein because they were so similar; however BC’s role in Wnt signalling led to it 
being recognised as a separate entity [33].  
PG is the only junctional component found in both desmosomes and adherens junctions. 
Within the desmosome PG links cadherins (desmoglein and desmocolin) to desmin 
(intermediate filament) via desmoplakin and plakophilin [33, 55]. Unlike in adherens junctions 
BC cannot replace the role of PG within the desmosome if PG is lost. In the adherens 
junction PG and BC can bind E-cadherin with equal affinity but in the desmosome PG binds 
desmoglein at a much higher affinity than BC [56, 57].  
As already mentioned PG and BC are structurally very similar and both are also involved in 
intracellular signalling not just in cell-cell adhesion. When the desmosome is disrupted, it 
causes PG to leave the junction and enter the cardiac progenitor cell nucleus [58, 59]. When 
in the nucleus PG has been shown to suppress BC transcription and allows activation of 
adipogenic genes [60]. See figure 2. 
The currently accepted hypothesis is that desmosomes are weakened by a mutated protein 
resulting in their disruption. The myocytes are no longer able to handle the haemodynamic 
shearing forces and become separated. These detached myocytes undergo apoptosis and 
are replaced by fibrosis under the influence of transforming growth factor beta (TGFB).  
Disruption of the desmosome with nuclear accumulation of PG causes the suppression of 








Connexin 43 (Cx43) is a transmembrane channel protein found in the gap junction. This 
protein is decreased at the gap junction in hearts diseased by many conditions including 
ischaemia, hypertrophy and cardiomyopathies [63]. Down regulation of Cx43 is associated 
with life threatening arrhythmias in these diseased hearts [64, 65]. Initial studies on patients 
with Naxos disease and Carvajal syndrome showed reduced expression of Cx43 at the gap 
junction is these conditions [50, 66] . 
In their sentinel paper, published in the New England Journal of Medicine, Asimaki et al 
stained for Plakoglobin in heart biopsies from ARVC patients and compared them with 
biopsies from normal controls, hypertrophic, ischaemic and dilated cardiomyopathies [67].  
They also stained for Cx43 and N-cadherin.  N-cadherin is used as an internal control to 
ensure adequate tissue quality for antigen retrieval.  
Their study showed a decrease (not complete absence) of PG in ARVC cases with no 
decrease in PG staining any of the other cases. This decreased PG staining was found in 
biopsies from any site in the heart, not just those from the “triangle of dysplasia”. They were 
correctly able to identify ARVC cases from other diseased hearts with a sensitivity of 91%, a 
specificity of 82% and a positive predictive value of 83%.  
They stressed that the difference in PG staining was due to a decreased level of protein 
expression, not due to a complete absence of the protein. To be able to demonstrate this 
they had to dilute the PG antibody to 1:50 000 before any clear differences between the 
diseases could be demonstrated. Also it was the combination of a decreased PG with 
normal N-cadherin that was needed. If both antibodies were decreased the tissue was felt to 





Asimaki et al used IF and confocal microscopy to establish a loss of PG expression, they did 
not use IHC. Traditionally immunofluorescence is used to identify the target protein but this 
is limited by the need for frozen material. Immunoperoxidase has been adapted to use on 
paraffin embedded, formalin fixed tissue as used in most laboratories [67]. The authors 
added a supplementary appendix to their article outlining the methodology needed to use 
immunoperoxidase rather than immunofluorescence. 
Follow up studies have had variable results in reproducing the results published by Asimaki 
et al. One study, using immunoperoxidase correctly identified ARVC cases 70% of the time 
by showing a decreased PG signal [68].  This study highlighted the importance of uniform 
handling of specimens and that staining needs to be done under identical conditions in order 
to obtain reliable results. They conclude with the remark that caution must be used when 
interpreting PG at the gap junction and note there is no gold standard by which ARVC can 
be diagnosed.   The authors highlighted the importance of the dilution of the PG antibody. In 
immunoperoxidase staining a dilution was used of 1:50 000 by Asimaki et al, published in 
their supplementary appendix, as well by Noorman et al [67, 68]. Munkholm et al needed to 
dilute their antibody to 1 : 300 000 to show reduced PG staining [69] 
Reduced PG immunoperoxidase signalling was found to have a sensitivity of 85% and 
specificity of 57% in ARVC patients by Munkholm et al [69]. These values are lower than 
those reported by Asimaki et al. In this study normal PG staining was reported in ARVC 
patients, resulting in a higher rate of false negatives. These authors concluded that reduced 
PG signalling is a frequent but not mandatory finding in ARVC. 
The specificity of a reduced PG signal has also been questioned. Reduced PG signalling 
was found in 43% of non ARVC cases by Munkholm et al [69]. The authors themselves and 
other experts do point out that these may be cases of concealed ARVC [68]. However, PG 
has been shown to be decreased in other histologically distinct diseases like sarcoidosis and 








Patients with the AR form of ARVC, Naxos disease, have the cardiomyopathy phenotype as 
well as palmoplanter keratoderma [10, 11].  
Keratoderma is the thickening of the stratum corneum of the skin and is either genetically 
inherited or acquired [71]. A mutation in PG in Naxos disease results in both the 
cardiomyopathy as well as the over-cornification and epidermal thickening of the palms and 
soles [72].  
Epidermal desmosomes provide the main structural adhesion between keratinocytes and 
resist mechanical stresses. These desmosomes are formed by transmembrane cadherins, 
which bind to PG, which in turn binds to the intermediate filament network via desmoplakin 
[73].PG is responsible for the anchorage of intermediate filaments to desmosomes [74]. 
A study of PG knockout mice showed loss of membranous staining of PG in the 
keratinocytes with associated inappropriate desmosome assembly and cell detachment [75]. 
However a study by Ruiz et.al shows the PG null mice had significant loss of desmosomes 
in the heart but not the epidermis [76]. 
The clinical significance of PG mutations in human epidermis is demonstrated by Pigors et 
al. They describe a homozygous nonsense PG mutation resulting in s lethal congenital 
epidermolysis bullosa [77]. Deqiang et al used immunofluorescence to reveal disrupted 
desmosomes and adherens junctions in PG mutant epidermis. They were also able to 












The literature fails to show a single test as being the gold standard for the diagnosis of 
ARVC outside of the autopsy / explanted heart setting. The diagnosis of ARVC remains a 
combined clinical, radiologic, genetic and pathologic diagnosis as is set out in the revised 
Task Force Criteria.  
FURTHER RESEARCH 
Additional studies need to look into the robustness of immunohistochemistry in the diagnosis 
of ARVC in cardiac biopsies. This immunohistochemistry also needs to be explored for its 






TABELS AND FIGURES 
Table 1: 1994 task force Criteria for diagnosis of right ventricular dysplasia                  
(Adapted from [19]) 
I - Global and/or regional dysfunction and 
structural alterations* 
MAJOR 
Severe dilatation and reduction of right 
ventricular ejection fraction with no (or 
only mild) LV impairment 
Localised right ventricular aneurysms 
(akinetic or dyskinetic areas with diastolic 
bulging) 
Severe segmental dilatation of the right 
ventricle 
MINOR 
Mild global right ventricular dilatation 
and/or ejection fraction reduction with 
normal left ventricle 
Mild segmental dilatation of the right 
ventricle 
Regional right ventricular hypokinesia 
 
II - Tissue characterisation of walls 
MAJOR 
Fibrofatty replacement of myocardium on 
endomyocardial biopsy 
 
III - Repolarisation abnormalities 
MINOR 
Inverted T waves in right precordial leads 
(V2 and V3) (people aged more than 12 yr; 
in absence of right bundle branch block) 
IV - Depolarisation/conduction 
abnormalities 
MAJOR 
Epsilon waves or localised prolongation 
(> 1 10 ms) of the QRS complex in right 
precordial leads (V1-V3) 
MINOR 
Late potentials (signal averaged ECG) 
 
V - Arrhythmias 
MINOR 
Left bundle branch block type ventricular 
tachycardia (sustained and non-
sustained) (ECG, Holter, exercise testing). 
Frequent ventricular extrasystoles (more 
than 1000/24 h) (Holter) 
  
VI - Family history 
MAJOR 
Familial disease confirmed at necropsy or 
surgery 
MINOR 
Familial history of premature sudden 
death (<35 yr) due to suspected right 
ventricular dysplasia. 
Familial history (clinical diagnosis based 
on present criteria) 
*Detected by echocardiography, angiography, magnetic resonance imaging, or radionuclide 





Table 2: 2010 Modified task force criteria      
(adapted from [45]) 
I - Global or regional dysfunction and 
structural alterations* 
MAJOR  
By 2D echo 
• Regional RV akinesia, dyskinesia, or 
aneurysm and 1 of the following (end diastole):  
○ PLAX RVOT > 32 mm (corrected for body 
size [PLAX/BSA] > 19 mm/m2)  
○ PSAX RVOT > 36 mm (corrected for body 
size [PSAX/BSA] > 21 mm/m2)  
○ or fractional area change < 33% 
By MRI 
• Regional RV akinesia or dyskinesia or 
dyssynchronous RV contraction and 1 of the 
following:  
○ Ratio of RV end-diastolic volume to BSA > 
110 mL/m2 (male) or >100 mL/m2 (female)  
○ or RV ejection fraction <40% 
By RV angiography 
• Regional RV akinesia, dyskinesia, or 
aneurysm 
MINOR 
By 2D echo 
• Regional RV akinesia or dyskinesia and 1 of 
the following (end diastole):  
○ PLAX RVOT > 29 to <32 mm (corrected for 
body size [PLAX/BSA] > 16 to < 19 mm/m2)  
○ PSAX RVOT > 32 to < 36 mm (corrected for 
body size [PSAX/BSA] > 18 to < 21 mm/m2)  
○ or fractional area change > 33% to < 40% 
By MRI 
• Regional RV akinesia or dyskinesia or 
dyssynchronous RV contraction and 1 of the 
following:  
IV - Depolarization/conduction 
abnormalities 
MAJOR  
• Epsilon wave (reproducible low-
amplitude signals between end of QRS 
complex to onset of the T wave) in the 
right precordial leads (V1 to V3) 
Minor 
• Late potentials by SAECG in >1 of 3 
parameters in the absence of a QRS 
duration of > 110 ms on the standard ECG 
• Filtered QRS duration (fQRS) >114 ms 
• Duration of terminal QRS < 40 μV(low-
amplitude signal duration) > 38 ms 
• Root-mean-square voltage of terminal 40 
ms < 20 μV 
• Terminal activation duration of QRS > 55 
ms measured from the nadir of the S wave 
to the end of the QRS, including R´, in V1, 
V2, or V3, in the absence of complete 
right bundle-branch block 
 
V - Arrhythmias 
MAJOR  
• Nonsustained or sustained ventricular 
tachycardia of left bundle-branch 
morphology with superior axis (negative or 
indeterminate QRS in leads II, III, and aVF 
and positive in lead aVL) 
MINOR 
• Nonsustained or sustained ventricular 
tachycardia of RV outflow configuration, 





○ Ratio of RV end-diastolic volume to BSA > 
100 to  
< 110 mL/m2 (male) or > 90 to < 100 mL/m2 
(female)  
○ or RV ejection fraction >40% to <  45% 
 
II - Tissue characterization of wall 
MAJOR  
• Residual myocytes < 60% by morphometric 
analysis (or < 50% if estimated), with fibrous 
replacement of the RV free wall myocardium in 
>1 sample, with or without fatty replacement of 
tissue on endomyocardial biopsy 
MINOR 
• Residual myocytes 60% to 75% by 
morphometric analysis (or 50% to 65% if 
estimated), with fibrous replacement of the 
RVfree wall myocardium in >1 sample, with or 
without fatty replacement of tissue on 
endomyocardial biopsy 
 
III - Repolarization abnormalities 
MAJOR  
• Inverted T waves in right precordial leads 
(V1, V2, and V3) or beyond in individuals 14 
years of age (in the absence of complete right 
bundle-branch block QRS > 120 ms) 
MINOR 
• Inverted T waves in leads V1 and V2 in 
individuals  14 years of age (in the absence of 
complete right bundle-branch block) or in V4, 
V5, or V6 
• Inverted T waves in leads V1, V2, V3, and V4 
in individuals  14 years of age in the presence 
of complete right bundle-branch block 
 
inferior axis (positive QRS in leads II, III, 
and aVF and negative in lead aVL) or of 
unknown axis 
• .500 ventricular extrasystoles per 24 
hours (Holter) 
 
VI - Family history 
MAJOR  
• ARVC/D confirmed in a first-degree 
relative who meets current Task Force 
criteria  
 • ARVC/D confirmed pathologically at 
autopsy or surgery in a first-degree 
relative  
• Identification of a pathogenic mutation† 
categorized as associated or probably 
associated with ARVC/D in the patient 
under evaluation 
Minor 
• ARVC/D confirmed pathologically or by 
current Task Force Criteria in second-
degree relative 
• History of ARVC/D in a first-degree 
relative in whom it is not possible or 
practical to determine whether the family 
member meets current Task Force criteria 
• Premature sudden death (<35 years of 
age) due to suspected ARVC/D in a first-
degree relative  
• ARVC/D confirmed pathologically or by 







Notes: Definite = 2 major OR 1 major + 2 minor; Borderline = 1 major + 1 minor OR 3 minor; Possible = 1 
major OR 2 minor. 
Abbreviations: PLAX, Parasternal Long-Axis; PSAX, Parasternal Short-Axis; RVOT, Right Ventricular 

































Cell adhesion complexes in the heart illustrating the critical cell adhesion structures involved 
in cardiomyocyte–cardiomyocyte connection. Adherens junctions, desmosomes and gap 







Figure 2: Molecular pathogenesis of ARVC (Adapted from Lombardi R. Curr Opin Cardiol 
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The diagnosis of arrhythmogenic right ventricular cardiomyopathy is dependent on clinical as 
well as histologic parameters, as set out in the revised task force criteria. At an 
ultrastructural level arrhythmogenic right ventricular cardiomyopathy is a disease of the 
cardiac desmosome. Plakoglobin is a desmosomal protein which, regardless of which 
arrhythmogenic right ventricular cardiomyopathy mutation is present, shows reduced 
expression in patients with arrhythmogenic right ventricular cardiomyopathy.  An 
immunohistochemical antibody has been developed against plakoglobin and recent 
publications have suggested that a decrease in immunohistochemical expression of 
plakoglobin is diagnostic for arrhythmogenic right ventricular cardiomyopathy. We stained 
cardiac biopsies from eleven cases of arrhythmogenic right ventricular cardiomyopathy, ten 
cases of human immunodeficiency virus associated cardiomyopathy, eight cases of dilated 
cardiomyopathy and eleven cases of transplanted donor hearts with plakoglobin and N-
cadherin immunolabels. The results showed that plakoglobin is a very difficult stain to 
interpret with only moderate inter-observer agreement (0.45 Kappa score). At best the 
sensitivity of this test is 72.73% but the specificity is only 32%. This study highlights the 
difficulties encountered in using plakoglobin immunohistochemistry and does not show a role 







arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease of the heart muscle 
characterised by non-ischaemic ventricular arrhythmias originating from the right heart 
muscle [1]. Pathologically it is defined by fibro-fatty replacement of the right ventricular 
myocytes [2].   
The diagnosis of ARVC is challenging both clinically and pathologically. Fibro-fatty 
replacement of cardiac myocytes is the histologic hallmark of the disease. The general 
consensus is that fat alone is not diagnostic of ARVC. Fat accompanied by replacement type 
fibrosis with or without degenerate myocytes is needed to make a histologic diagnosis [3-5].  
This fibro-fatty replacement should also be transmural within the right ventricular (RV) 
myocardium, as seen in the autopsy setting or in an explanted heart [2, 4]. Endomyocardial 
biopsies are not transmural and are often taken from the region of the uninvolved septum [3]. 
This is not of much value in the clinical setting and in 1993 a task force was established to 
set out parameters on which to make a diagnosis of ARVC. The task force established six 
areas where the evidence indicated a diagnosis of ARVC could be made. These included (I) 
Global/regional dysfunction and structural alterations; (II) Tissue characterisation of walls; 
(III) Repolarisation abnormalities; (IV) Depolarisation/conduction abnormalities; (V) 
Arrhythmias; (VI) Family history [3, 13]. 
Cardiac myocytes have a unique structure, the intercalated disc, which allows electrical 
impulses to pass from the end of one myocyte into the adjacent myocyte. Within this 
intercalated disc are gap junctions, which are responsible for electrical coupling of the 
myocytes. These gap junctions allow free passage of ions across membranes of adjoining 
myocytes  [6]. Gap junction remodelling occurs in most forms of heart disease, including 
dilated cardiomyopathies, ischaemic heart disease, hypertrophic conditions and ARVC [7]. 
The major protein found in gap junctions is connexin 43 (Cx43)[8]. The electrical integrity of 




junction [9, 10]. These adhesion junctions are formed by cadherins (E-cadherin and N-
cadherin) on opposite cell membranes hooking together to form a zipper-like structure. The 
cadherin’s tail in the cytoplasm binds either plakoglobin (PG) or B-catenin (BC).  PG is the 
only junctional component found in both desmosomes and adherens junctions. Within the 
desmosome PG links cadherins (desmoglein and desmocolin) to desmin (intermediate 
filament) via desmoplakin and plakophilin [11, 12]. See figure 1. 
Up to 50 % of ARVC cases are autosomal dominant (AD) in transmission with variable 
expression and penetrance [13]. Mutations have been identified in the five major 
components of the desmosome. These genes are: PKP2 – plakophilin 2; DSG2 – 
desmoglein 2; DSP – desmoplakin, DSC2 – desmocollin 2 and JUP – plakoglobin (PG) [14]. 
The majority of mutations are in the PKP2 gene. However, regardless of which desmosomal 
gene has the mutation there is always a decrease in plakoglobin protein at the intercalated 
disc. This decreased expression of PG has therefore become an area of interest as a 
possible diagnostic marker for ARVC [14, 15]. 
An antibody to PG has been developed and is commercially available in both 
immunofluorescence and immunoperoxidase forms. It has been suggested that this can be 
used to diagnose ARVC in cardiac biopsy specimens [16]. Traditionally immunofluorescence 
is used to identify the target protein but this is limited by the need for frozen material. 
Immunoperoxidase has been adapted for use on paraffin embedded, formalin fixed tissue as 
used in most laboratories [16].  
The immunohistochemical diagnosis of ARVC is based on identifying a decrease in the 
staining intensity of PG, as a marker of the decreased PG expression, at the intercalated 
disc [16].  This decrease in staining intensity can be compared to the N-cadherin staining, 
which is present at the intercalated disk, but not the desmosome (i.e. the N-cadherin acts as 
an internal control of tissue quality).  
Although the sentinel paper showed excellent sensitivity and specificity, follow up studies 




a decreased staining intensity of PG in other histologically distinct diseases like sarcoidosis 
and giant cell myocarditis [19]. 
In this study the authors aimed to assess the sensitivity and specificity of PG 
immunohistochemistry on cardiac biopsies from 3 different diseases (ARVC, dilated 





2. MATERIALS AND METHODS 
2.1. Study group 
Paraffin embedded cardiac biopsies were obtained from the National Health Laboratory 
service (NHLS)/Groote Schuur Hospital (GSH) archives.  In total 11 cases of ARVC (These 
cases were identified by Professor Mayosi - principle investigator ARVC registry of South 
Africa. The diagnosis of ARVC was made using clinical and radiologic characteristics as set 
out by the ARVC task force criteria), 10 cases of HIV associated cardiomyopathy, 8 cases of 
dilated cardiomyopathy (DCMO) and 11 cases of transplanted donor hearts to use as normal 
controls, were collected. 
2.2. Immunohistochemistry 
To optimise the antibodies prior to use on the cardiac biopsies, tissue was obtained from 
autopsy and explanted hearts from patients with ARVC, dilated cardiomyopathy and patients 
dying from non-cardiac causes.  The immunohistochemical stains used were N-cadherin 
(Sigma, UK; diluted 1:100, EDTA buffer), G-catenin (PG) (Sigma, UK; diluted 1:50 000 then 
1: 60 000, citrate buffer) and Connexin 43 (Zymed, UK; diluted 1:100, EDTA buffer). 
Although the antibodies used were identical to those used by Asimaki et al, as set out in their 
supplementary appendix, we could not exactly reproduce their findings on the 
autopsy/explanted samples. Despite all efforts with dilutions and different retrieval systems, 
it was not possible to eliminate non-specific background staining on the Cx43 slides. The 
authors failed to show a loss of Cx43 staining in the diseased hearts as compared to the 
control tissue. For this reason it was decided to not include Cx43 in the rest of the study.  
Although Asimaki et al were able to show a decrease in PG staining at 1:50 000 dilutions, 
this study only observed this difference at a dilution of 1: 60 000. 
Each biopsy was then stained with N – Cadherin and PG. Using the NHLS 
immunohistochemical protocol sections were cut at 3 microns and floated onto 




leaving slides on hot plate (60°C). The slides were dewaxed in xylol and rehydrated in 
graded alcohols. Antigen retrieval was performed using citrate or EDTA depending on 
antibody used (see above). Endogenous peroxidase activity was blocked by treating the 
slides with 1% hydrogen peroxide in methanol for 5 minutes. Normal goat serum (1:20) was 
used to block for non-specific background staining by treating slides with normal goat serum 
(1:20) for 5 minutes. The appropriately diluted primary antibody was then applied for 45 
minutes and rinsed thoroughly with phosphate buffered saline (pH 7.6).  Envision reagent, 
goat anti-rabbit antibody (secondary antibody) was applied for 25 minutes and the slides 
were again washed with buffered saline. A chromogenic substrate (1ml buffer and 1 drop 
diaminobenzidene) was applied for 3 minutes and washed before slides were immersed in 
1% copper sulphate for 3 minutes. Haematoxylin was used as a counter stain and rinsed 
with Scott’s tap water. 
2.3. Immunohistochemical assessment 
All cases were assessed by two pathologists (N.J.M. and H.C.W.) who were blinded to the 
clinical diagnosis. Each stain (PG and N-cadherin) was scored with a semi-quantitative 
assessment of intensity using the following criteria: 0, negative – no typical staining seen, 
even at 40 x objective; 1, weak – typical staining seen but only convincing when using 40 x 
objective; 2, moderate – typical staining seen, convincing using 20 x objective; 3, strong – 
obvious, typical staining at 4 x objective. See figure 2 and 3. (A similar semi-quantitative 
scoring system has been used in assessing the BRAF V600E antibody in colorectal 
carcinoma [21]).  Typical staining had to be seen as a linear stain at the gap junction, 
perpendicular to the long axis of the myocyte, to be considered positive. 
The same cases were then assessed qualitatively by the same two pathologists, without 
using a quantitative scoring system. The N-cadherin staining intensity was compared to the 
PG staining intensity of the same case.  If the PG was weaker in staining intensity than the 
N-cadherin (i.e. less PG protein expression than N-cadherin protein expression) a diagnosis 




Each case was given an immunohistochemical diagnosis of: a) ARVC, b) possible ARVC or 
c) not ARVC. This diagnosis was based on the scoring intensity difference between the N-
cad and PG. In ARVC the PG is expected to be weaker than N-cad hence the N-cad score 
was subtracted from the PG score. For example an N-cad score of 3 subtracted from a PG 
score of 1 would result of a value of -2.  
If the N-cad scored 0 the case was discarded as the internal control had failed.  If the G-cat 
stained the same (value 0) or stronger (value +1 to +2) than the N-cad, the case was 
diagnosed as not ARVC, see example Figure 4. A value of -1 was considered possible 
ARVC and a value of -2 or -3 was diagnostic of ARVC, see example figure 5. See Table 1. 
 
2.4. Statistical analysis  
Interobserver variability was determined using Landis and Koch’s measurement of observer 







3.1. Using the semi-quantitative assessment 
Using the semi-quantitative scoring method N.J.M. had a sensitivity of 38.46% [95% 
CI: 14.00% to 68.36%] and a specificity of 39.29% [95% CI: 21.53% to 59.42%].  
H.C.W. had a sensitivity of 23.08% [95% CI: 5.31 % to 53.80 %] and a specificity of 64.29% 
[95% CI: 44.07% to 81.33%]. 
 If the “possible ARVC” were excluded from the statistical analysis the specificity of the test 
increased but the sensitivity decreased. See Table 2. 
There was only fair agreement between N.J.M and H.C.W (Kappa 0.085). 
 
3.2. Using qualitative assessment 
Interobserver agreement and sensitivity of the test both improved when the 
immunohistochemical stains were assessed in a qualitative manner.  However the specificity 
of the test decreased. See Table 2. 
N.J.M sensitivity was 72.73% [95% CI: 39.08% to 93.65%] and specificity was 32% [95% CI: 
14.99% to 53.50%]. H.C.W sensitivity was 63.64% [95% CI: 30.88% to 88.85%] and 
specificity was 40% [95% CI: 21.16% to 61.32%]. The Cohen’s kappa agreement was 
moderate (0.45). 
In a similar way to where “Possible ARVC” cases were excluded for in the semi-quantitative 
analysis, borderline diagnostic cases can be excluded from the qualitative analysis: Cases 
which had discordant diagnosis between the pathologists represent those where there is 
diagnostic difficulty in interpreting the difference in staining. Where there was interpretation 
agreement between the two pathologists the authors were able to demonstrate a reduced 
signal of PG in 70% (7/10) of the ARVC cases. However, PG was also decreased in 60% 




Example of a false positive diagnosis is given as figure 6. Both pathologists qualitatively 
diagnosed this case as ARVC, based on the striking loss of PG staining. However, this 
represents a biopsy from an HIV cardiomyopathy. 
 
An example of a false negative diagnosis is given as figure 7. Both pathologists qualitatively 
diagnosed this case as “Non- ARVC” as no difference in N-cad and PG staining was 






This is not an easy immunohistochemical stain to evaluate, as evidenced by only fair 
interobserver agreement (kappa value of 0.085) when a semi-quantitative method is applied. 
Other immunohistochemical stains where semi-quantitative scores are given, for example 
Her2Neu in breast cancer, clear guidelines exist for these staining patterns and intensity 
[20]. No guidelines are available for pathologists in trying to interpret a loss of staining of PG 
versus N-cadherin and this makes it difficult to use this test in routine practice.  This lack of 
standardization in scoring these cases resulted in both poor sensitivities (38.46 and 23.08 
%) and specificities (64.29 and 73.33%). When the borderline or ambiguous cases labelled 
“Possible ARVC” (i.e. those showing only a scoring intensity difference of -1) were excluded 
from the statistical analysis then an increased specificity was noted (73.33 and 85.71%) but 
at the expense of the sensitivity (27.27 and 0%). Therefore, a strong staining intensity 
difference (-2 or -3) between PG and N-cadherin could be used to confirm a diagnosis of 
ARVC, but not exclude it as the sensitivity of the test is too low. 
If using the test in a qualitative manner the Kappa score increased to 0.45 - moderate 
agreement between the observers.  The qualitative assessment also allowed for an 
improved sensitivity (72.73 and 63.64%) but the specificity decreased (32 and 40%) when 
compared to the semi-quantitative evaluation. The decreased specificity is due to a decrease 
in staining intensity difference being reported in the non ARVC cases. This trend was 
accentuated when the cases with discrepant diagnosis between pathologists were excluded.  
Where the two pathologists agreed there was a loss of staining a diagnosis of ARVC was 
made correctly in 7/10 cases of cases but a decreased staining, and hence a diagnosis of 
ARVC, was also observed in 12/17 of the non ARVC cases.  
Although a qualitative analysis allows increased numbers of cases of ARVC to be 
diagnosed, it loses the specificity of the semi-quantitative analysis. 
These results failed to demonstrate a role for PG immunohistochemistry in the diagnosis of 




Cases of concealed ARVC may have resulted in the poor specificity of the test. However, the 
cases of HIV associated cardiomyopathy have all been extensively worked up and have a 
known pathogenesis (as opposed to dilated CMO where there is clinical overlap) and the 
transplant biopsies represent tissue taken from normal hearts where the probability of 
concealed ARVC is remote. 
This study used archival cases where there was no uniform handling of the biopsy material, 
which may explain the poor sensitivities and specificities that are reported. However, all the 
cases were stained in the same batch, so variations in the antibody concentration and 
antigen retrieval techniques are unlikely to be the cause of the poor outcomes. Also, in 
everyday practice it is unlikely that cardiac biopsies are going to be batched for the 
immunohistochemistry; each case will be stained and reported as it comes into the 
laboratory.  
This is a difficult immunohistochemical stain to interpret and even two pathologists with 
extensive exposure to this stain at best only achieved a kappa agreement that was 
moderate. This is likely due to the small nature of the cardiac biopsies themselves, as 
opposed to staining done on explanted or autopsy material. Also, the specific staining site 
(along the gap junction) may not be seen if the myocytes are cut along the short axis.  
The antibody dilution seems to be critical when using PG immunohistochemistry in cardiac 
diseases. A reduced PG signal was shown to have a specificity of 82% by the Asimaki et al, 
and only their ARVC cases showed a decreased staining with no decrease in PG staining in 
any of the other cases. They were correctly able to identify ARVC cases from other diseased 
hearts with a sensitivity of 91%. They stressed that the difference in PG staining was due to 
a decreased level of protein expression, not due to a complete absence of the protein. To be 
able to demonstrate this they had to dilute the PG antibody to 1:50 000 before any clear 




Personal communication by the author with Dr Asimaki revealed that many laboratories from 
around the world have tried to use immunohistochemistry and have reported “varying 
success”.   
Follow up studies have also had variable success in reproducing the results published by 
Asimaki et al. The study by Noorman et al, using immunoperoxidase, correctly identified 
ARVC cases 70% of the time by showing a decreased PG signal [18].  This study highlighted 
the importance of uniform handling of specimens and that staining needs to be done under 
identical conditions in order to obtain reliable results. They conclude with the remark that 
caution must be used when interpreting PG at the gap junction and note that there is no gold 
standard by which ARVC can be diagnosed.   The authors highlighted the importance of the 
dilution of the PG antibody. An immunoperoxidase staining dilution of 1 : 50 000 was used 
by Asimaki et al, published in their supplementary appendix, as well as by Noorman’s et al 
[16, 18]. However in the publication by Munkholm et al a dilution of 1 : 300 000 was needed 
to show reduced PG staining [17] 
Reduced PG immunoperoxidase signalling was found to have a sensitivity of 85% and 
specificity of 57% in ARVC patients by Munkholm et al [17]. These values are lower than 
those reported by Asimaki et al. In this study normal PG staining was reported in ARVC 
patients, resulting in a higher rate of false negatives. These authors concluded that reduced 
PG signalling is a frequent but not mandatory finding in ARVC.  
The specificity reported in Asimaki et al study is in contrast to that of Noorman et al, in which 
reduced PG signalling was found in 43% of non ARVC cases. The authors themselves and 
other experts point out that these may be cases of concealed ARVC [18]. PG has been 
shown to be decreased in other histologically distinct diseases like sarcoidosis and giant cell 
myocarditis [19] where there is no probability of underlying occult ARVC. 
Suggestions to improve the interpretation of this PG immunohistochemical stain include the 
use of a red chromagen. The presence of paranuclear lipofuscin can be misinterpreted as 




distinguish from lipofuscin. It also is likely that it is easier to use this antibody in an 
immunofluorescence setting where the interpretation is more obvious.  
It is also possible that more consistent results could be obtained if tissue handling and 
staining protocols are implemented in laboratories in an attempt to decrease exogenous 
factors interfering in the staining with PG. 
 
It also needs to be emphasised that Asimaki et al published their results based on 
immunofluorescence and confocal microscopy. They only gave a protocol for conversion to 
immunohistochemistry, not results from immunohistochemistry. It is likely that the variability 
and confounding factors which exist in immunohistochemistry as compared to 
immunofluorescence and confocal microscopy resulted in these discrepant results when it 
comes to demonstrate a loss of PG staining. 
 
Findings from this study, as well as others, highlight both the technical difficulties in the pre-
analytical stage of PG immunohistochemistry and the analytical stage of interpreting the 
results. A marked loss of PG immunohistochemical staining, when compared to N-Cadherin 
(staining intensity difference of -2 or -3), could be used to confirm a diagnosis of ARVC but 
not exclude it from the differential diagnosis. The authors therefore believe this stain should 
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Figure 1: Schematic of the intercalated disc (adapted from Guo D; J Mol Cell Cardiol 2011 
[55]). a-cat = alpha-catenin; B-cat = Beta – catenin; Cx43 = Conexin 43; DP= desmoplakin; 













Figure 2: Staining intensity of placoglobin. A = score 3, 4x objective; B = score 2, 20x 








Figure 3: Staining intensity of Placoglobin at 40x objective 







Figure 4: Staining intensity difference between Placoglobin and N-cadherin case number 40. 
A = N-cadherin, score 3; B = Placoglobin, score 3.  






Figure 5: Staining intensity difference between Placoglobin and N-cadherin, case number 26 
A = N-cadherin, score 3; B = Placoglobin, score 0.  







Figure 6: False positive diagnosis of ARVC, qualitative assessment, case number 8 






Figure 7: False negative diagnosis of ARVC, qualitative assessment, case number 15 







LEGENDS FOR FIGURES 
 
Figure 1: Schematic of the intercalated disc. a-cat = alpha-catenin; B-cat = Beta – catenin; 
Cx43 = Conexin 43; DP= desmoplakin; DSC = Desmocollin; DSG = Desmoglein; N-cad = N-
cadherin; PG = Plakoglobin; PP = Plakophilin. 
Figure 2: Staining intensity of placoglobin. A = score 3, 4x objective; B = score 2, 20x 
objective; C = score 1, 40x objective; D = score 0, no staining at any magnification. 
 
Figure 3: Staining intensity of Placoglobin at 40x objective 
A = score 0; B = score 1; C = score 2; D = score 3 
 
Figure 4: Staining intensity difference between Placoglobin and N-cadherin case number 40. 
A = N-cadherin, score 3; B = Placoglobin, score 3.  
Staining intensity difference = 0, therefore an immunohistochemical diagnosis of non ARVC. 
 
Figure 5: Staining intensity difference between Placoglobin and N-cadherin case number 26. 
A = N-cadherin, score 3; B = Placoglobin, score 0.  
Staining intensity difference = - 3, therefore an immunohistochemical diagnosis of ARVC. 
 
Figure 6: False positive diagnosis of ARVC, qualitative assessment, case number 8 
A = N- cadherin; B = Placoglobin 
Figure 7: False negative diagnosis of ARVC, qualitative assessment, case number 15 




























































Diagnostic category Staining intensity difference  
(N-cadherin score subtracted from PG score) 
ARVC -2 to -3 
Possible ARVC -1 








   0.085 
All diagnostic 
categories 
Sensitivity 36.46% [95% CI:  
14.00 % to 68.36 %] 
23.08% [95% CI: 
5.31 % to 53.80 %] 
 
 Specificity 39.22% [95% CI:  
21.53 % to 59.42 %] 
64.29% [95% CI:  




Sensitivity 27.27% [95% CI:  
6.35 % to 60.92 %] 
0% [95% CI:  
0.00 % to 31.03 %] 
 
 Specificity 73.33% [95% CI:  
44.91 % to 92.05 %] 
85.71% [95% CI:  




   0.45 
 Sensitivity 72.73% [95% CI: 
39.08% to 93.65%] 
63.64% [95% CI: 
30.88% to 88.85%] 
 
 Specificity 32% [95% CI: 
14.99% to 53.50%] 
40% [95% CI: 
21.16% to 61.32%] 
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APPENDIX 2 – Raw data for subjective IHC assessment 
 








HCW DIAGNOSIS NJM Diagnosis Clinical Diagnosis 
1 1 1 DCM 
2 2 1 HIV 
3 1 1 HIV 
4 1 1 HIV 
5 2 2 ARVC 
6 2 1 HIV 
7 1 1 ARVC 
8 1 1 HIV 
9 1 2 Tx 
10 1 2 Tx 
11 1 1 DCM 
12 1 1 ARVC 
13 1 1 Tx 
14 2 1 DCM 
15 2 2 ARVC 
16 2 1 HIV 
17 1 1 ARVC 
18 2 2 Tx 
19 1 2 Tx 
21 1 1 Tx 
22 1 1 DCM 
23 2 2 HIV 
24 2 1 HIV 
25 2 1 ARVC 
26 1 1 ARVC 
27 1 1 ARVC 
28 1 1 ARVC 
29 2 2 DCM 
30 1 1 ARVC 
31 2 2 HIV 
32 1 1 Tx 
33 1 1 Tx 
36 1 1 Tx 
39 2 2 ARVC 
40 1 1 DCM 
41 2 2 DCM 
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